SuperworthMeiraGTx price to free cash flow MGTX
Market value divided by free cash flow over the last twelve months, since 2019.
- Today, Oct 23, 2026
- 84.5×
- 7-year median
- 40.4×
- Against its 7-year history
- 68th
- percentile: 0 is its lowest day, 100 its highest
- 7-year range
- 18.3× to 310×
- Peer median
- 26.8×
MeiraGTx's price to free cash flow is 84.5× as of Oct 23, 2026.
That is above its 7-year median of 40.4×, higher than on 68% of days in the last 7 years.
Over that time it ranged from 18.3× in Oct 2019 to 310× in Jul 2026.
The median for 3 biotech stocks of a similar size is 26.8×.
Price to free cash flow over time
Year by year
| Year | End of year | Low | High |
|---|---|---|---|
| 2026 so far | 84.5× | 84.5× | 310× |
| 2025 | n/m a value too high to mean anything | ||
| 2024 | n/m a value too high to mean anything | ||
| 2023 | n/m a value too high to mean anything | ||
| 2022 | n/m a value too high to mean anything | ||
| 2021 | n/m a value too high to mean anything | ||
| 2020 | 42.9× | 31.4× | 48.5× |
| 2019 | 42.2× | 18.3× | 44.6× |
Against its peers
Companies in Biotechnology nearest MeiraGTx's size, closest first, today.
| Company | Price to free cash flow |
|---|---|
| MGTXMeiraGTx | 84.5× |
| VCELVericel | 35.3× |
| ADMAAdma Biologics | 20.5× |
| PLXProtalix BioTherapeutics | 26.8× |
| Peer median | 26.8× |
What the price to free cash flow tells you
Market value divided by free cash flow: the cash left after running the business and paying for equipment. Cash is harder to manage than accounting earnings, so many investors trust this more than PE.
Lumpy: a big year of building factories drops cash flow and inflates the ratio without the business getting worse.
More on MeiraGTx
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.